… , only few ACE-2-based peptides were screened and proposed. In … antiviral peptides
that were known to work against SARS-CoV-1, targeting the RBD of the S protein of SARS-CoV-2. …

… coronavirus 2 (SARS-CoV-2) is a β-coronavirus that emerged in late 2019 from the Wuhan
region of China [1,2… Enfuvirtide (Fuzeon or T-20) was the first antiviral peptide approved for …

… coronavirus 2 (SARS-CoV-2) infectious disease (COVID-19) … is an urgent requirement of
suitable antiviral agent/therapy to … of SARS-CoV-2 infection is the crosstalk between the SARS-…

… novel therapeutics against SARS-CoV-2. Despite these benefits, antiviral peptides are
particularly … of using nanotechnology to deliver antiviral peptides against SARS-CoV-2 infection. …

… peptide inhibitors of SARS-CoV-2 M pro , we sought to utilize RaPID, which allows the screening
of >10 12 cyclic peptides … However, functional SARS-CoV-2 M pro is a homodimer with …

… infection and also prepare for future clinical application research for SARS-CoV-2 therapy.
We will further simulate the antivirus peptide with modification and test the blocking effect in …

… or exert broad antiviral activity. Here, we summarize the current status of peptides inhibiting
SARS-CoV-2 entry and outline the strategies used to design peptides targeting the ACE2 …

… In search of an effective antiviral against COVID-19, we believe AVPs could represent
one of the potential classes of new antiviral agents against SARS-CoV-2. It is fascinating to …

… In our study, we only examined those peptide molecules with known antiviral activity.
Based on antiviral activity, we screened 215 antiviral peptides from 5820 peptides. Additional …

… On the other hand, few approved antiviral treatments demonstrated … SARS-CoV-2 papin-like
protease. The current work aims to design an in-silico peptide inhibitor of the SARS-CoV-2 …